A novel agent is for treating or preventing a glioma. A marker for malignancy of a brain tumor and a prognostic marker for a brain tumor can be used in a method for determining malignancy of a brain tumor and a method for determining a prognosis for a brain tumor patient. The agent for treating or preventing a glioma can include an HVEM inhibitor as an active ingredient. The marker for malignancy of a brain tumor and the prognostic marker for a brain tumor can each include an HVEM protein or an HVEM gene. The method for determining malignancy of a brain tumor and the method for determining a prognosis for a brain tumor patient can each include measuring an HVEM expression amount in a biological sample of a subject.

Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.

Methods are provided for assaying bladder-associated samples. Aspects of the methods include detecting per cell programmed-death ligand 1 (PD-L1) expression in a bladder-associated sample. In some instances, the methods include detecting whether an immune cell that expresses PD-Ll above a predetermined threshold is present in a bladder-associated sample and/or detecting a PD-L1-aneuploid-to-PD-L1-epithelial ratio of a bladder-associated sample. Aspects of the methods may also include identifying whether a malignant bladder-associated neoplasia is present. Methods are also provided for treating a subject for a malignant bladder-associated neoplasia, wherein aspects of such methods include administering a therapeutic to a subject having an identified malignant bladder-associated neoplasia. In addition, kits that find use in practicing the subject methods are also provided.

Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human CEACAM5 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising an anti-human CEACAM5 antibody Fab fragment and a ligand, the fragment comprising a heavy chain fragment including a heavy chain variable region consisting of a specific amino acid sequence and a light chain including a light chain variable region consisting of a specific amino acid sequence, or a conjugate comprising a ligand, a spacer, and a peptide linker, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.

A marker may determine sensitivity to an anti-cancer agent early after the start of treatment with the anti-cancer agent. The anti-cancer agent may include oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker including one or more molecules selected from the group consisting of 2AMAD, 2ABA, 2CYPR, 5OPRO, 6AHXA, ADEN, ASP, BETNC, CARB, CSSG, DOPM, GGLCY, GSSG, HYPT, METSF, N6MDA, NOMTR, PHEP, PRO, and RIB5P.

The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a N detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.

Disclosed herein are methods of detecting and treating checkpoint inhibitor responsive cancers comprising calculating, determining, or obtaining PD-L1 expression, CD8A expression, and tumor content from a cancer specimen.

Constructs comprising an antibody moiety that specifically binds to Labyrinthin or a portion thereof and an effector domain are provided. Also provided are methods of making and using these constructs and compositions thereof.

Monovalent antibodies such as nanobodies that are specific for galectin-7 are described. These monovalent antibodies are able to interfere with the dimerization of galectin-7, and thus may be used for the treatment of diseases associated with dysregulated galectin-7 expression and/or activity, such as certain types of cancers as well as eye diseases or conditions associated with pathological neovascularization or angiogenesis.

The present invention provides a method for treating SWI/SNF complex-deficient cancers comprising a glutathione (GSH) metabolic pathway inhibitor, a pharmaceutical composition comprising a glutathione (GSH) metabolic pathway inhibitor for therapy in SWI/SNF complex-deficient cancers, and a glutathione (GSH) metabolic pathway inhibitor for use in treating SWI/SNF complex-deficient cancers. The present invention also provides a method for detecting and/or selecting a susceptible patient to a glutathione (GSH) metabolic pathway inhibitor.